Hematologic Adverse Events Associated With Prolonged Valganciclovir Treatment in Congenital Cytomegalovirus Infection

The Pediatric Infectious Disease Journal
12 Feb, 2019 ,

Ziv et.al. studied the adverse events in Infants with cCMV treated with valganciclovir for a period of one year. They concluded that even though valganciclovir treatment is safe but a close monitoring of white blood cell count and hemoglobin levels is advisable. Amongst all, drug induced anemia should be a primary concern.